Put Volume Explodes on Conatus Pharmaceuticals Inc. (CNAT)

Conatus Pharmaceuticals Inc (CNAT) put volume is running at 12 times the expected intraday clip

Digital Content Group
Jan 15, 2015 at 1:58 PM
facebook twitter linkedin

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is hovering around breakeven today at $5.37. Despite this ho-hum price action, puts are flying off the shelves at 12 times the average intraday rate. By the numbers, 5,394 puts are on the tape, compared to roughly 300 calls.

Almost all of the put volume transpired as one block of 5,000 contracts at the January 2015 10 strike. According to data from the International Securities Exchange (ISE), these deep in-the-money positions were sold to close ahead of this Friday night's expiration.

Technically speaking, CNAT has had a brutal year, exacerbated by a recent gap lower on disappointing drug trial results. Year-over-year, the stock has lost more than half of its value.

Given these technical struggles, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) puts have been targeted of late, relative to calls. The stock's 10-day ISE, Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.99 indicates puts have been bought to open at twice the rate of calls over the last two weeks.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners